CELLINK announces extension of collaboration with AstraZeneca to use CELLINKs’ 3D-bioprinting and associated technology for drug discovery
CELLINK scientists will continue to work side-by-side in AstraZeneca labs, aiming to speed discovery of new therapiesCELLINK, focused on the commercialization of innovative technologies for bioprinting and associated technologies for preparation and analysis of 3D-bioprinted tissues, announced today that the company has renewed its agreement to collaborate with the global biopharmaceutical company AstraZeneca for an additional 12 months. CELLINK will provide bioprinters and bioinks to accelerate the exploration of new disease targets in AstraZeneca’s main therapeutic areas, including